WHRN Human Pre-designed siRNA Set A contains three designed siRNAs for WHRN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WIF1 Human Pre-designed siRNA Set A contains three designed siRNAs for WIF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WIPF1 Human Pre-designed siRNA Set A contains three designed siRNAs for WIPF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WIPF3 Human Pre-designed siRNA Set A contains three designed siRNAs for WIPF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WIPI1 Human Pre-designed siRNA Set A contains three designed siRNAs for WIPI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WIPI2 Human Pre-designed siRNA Set A contains three designed siRNAs for WIPI2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WIZ Human Pre-designed siRNA Set A contains three designed siRNAs for WIZ gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis[1].

WJM-715 is an antimalarial agent with an EC50 of 0.015 μM by trageting STAR-related lipid transfer protein (PfSTART1) with a KD of 14 nM[1].

WLS Human Pre-designed siRNA Set A contains three designed siRNAs for WLS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNK1 Human Pre-designed siRNA Set A contains three designed siRNAs for WNK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNK2 Human Pre-designed siRNA Set A contains three designed siRNAs for WNK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNK3 Human Pre-designed siRNA Set A contains three designed siRNAs for WNK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNK4 Human Pre-designed siRNA Set A contains three designed siRNAs for WNK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors[1].

Wnt/β-catenin-IN-2 (Compound 3235-0367) is a Wnt/β-catenin signaling pathway inhibitor, with IC50 and KD values of 7.1 and 2.5 μM, respectively. Wnt/β-catenin-IN-2 can be used for the research of cancer[1].

Wnt/β-catenin-IN-3 (compound 17) is a Wnt/β-catenin inhibitor with low micromolarGI50s against various cancer cells. Wnt/β-catenin-IN-3triggers G2/M cell cycle arrest though activation of p53-p21 pathway as well as intrinsic and extrinsic apoptotic death of colon cancer cells[1].

WNT1 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT10A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT10A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT10B Human Pre-designed siRNA Set A contains three designed siRNAs for WNT10B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT11 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT16 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT2 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT2B Human Pre-designed siRNA Set A contains three designed siRNAs for WNT2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT3 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT3A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT4 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT5A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT5B Human Pre-designed siRNA Set A contains three designed siRNAs for WNT5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT6 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT7A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT7A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT7B Human Pre-designed siRNA Set A contains three designed siRNAs for WNT7B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT8A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT8A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT8B Human Pre-designed siRNA Set A contains three designed siRNAs for WNT8B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT9A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT9A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNT9B Human Pre-designed siRNA Set A contains three designed siRNAs for WNT9B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation[1].

Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research[1].

WRAP53 Human Pre-designed siRNA Set A contains three designed siRNAs for WRAP53 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WRN Human Pre-designed siRNA Set A contains three designed siRNAs for WRN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

WRN inhibitor 6 (compound 3ci) is a potent WRN inhibitor. WRN inhibitor 6 induces apoptosis. WRN inhibitor 6 increases the expression of p-p53, P-Chk2, γH2AX expression[1].